Clinical trial registry record

Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 23, 2019.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01972789
Last registry update
October 23, 2019
Status
Completed
Phase
Phase 4
Sponsor
Novartis Pharmaceuticals
Enrollment
349
Countries
Australia
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
Evidence population
Human clinical study registration
Participants
349
Population
ALL · 50 Years
Duration
2013-10-31 to 2017-02-28
Intervention
Ranibizumab
Comparator
Not reported
Outcomes measured
Mean Change in Best-corrected Visual Acuity (BCVA) From Baseline to 24 Months. — Baseline to month 24; Mean Change in BCVA From Baseline to Month 12. — Baseline to month 12; Mean Change in Central Retinal Thickness (CRT) From Baseline to Month 12 and 24. — Baseline to month 12 and month 24; Mean Number of Injections From Baseline to Month 12 and 24 — Baseline to month 12 to month 24.; Mean Change in Area of New and Existing Geographic Atrophy From Baseline to Month 12 and 24. — Baseline to months 12 an…; Proportion of Patients Showing Newly Developed Geographic Atrophy (GA) at Months 12 and 24 — Months 12 and 24; Proportion of Patients Showing no IRF and SRF at Months 2, 12 and 24. — Months 2, 12 and 24.; Proportion of Patients Showing Greater Than or Equal to 15 Letters Early Treatment Diabetic Retinopathy (ETDRS) Gain Fr…; Proportion of Patients Showing Less Than 15 Letters ETDRS Loss From Baseline to Month 12 and 24. — Baseline to months 1…; Number of Participants With the Genotypes Associated With Age-Related Macular Degeneration (AMD) and Response to Treatm…; Proportion of Patients With Both SRF (Sub-retinal Fluid) and IRF (Intra-retinal Fluid) Who Despite Monthly Treatment do…; The Number of Times a Participant Needs to Return to Monthly Treatments During the 24 Months. — Month 24
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON